Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 14/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 12/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.94 |
| ▸ | PDGFRA | P16234 | 3/20 | 1.00 |
| ▸ | RAD52 | P43351 | 1/20 | 1.00 |
| ▸ | ABL2 | P42684 | 7/20 | 0.94 |
| ▸ | LYN | P07948 | 3/20 | 0.94 |
| ▸ | SRC | P12931 | 2/20 | 0.94 |
| ▸ | SYK | P43405 | 2/20 | 0.94 |
| ▸ | PLK4 | O00444 | 1/20 | 0.94 |
| ▸ | DDX3X | O00571 | 1/20 | 0.94 |
| ▸ | GAK | O14976 | 1/20 | 0.94 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.94 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.94 |
| ▸ | CA12 | O43570 | 1/20 | 0.94 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.94 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.94 |
| ▸ | EGFR | P00533 | 1/20 | 0.94 |
| ▸ | CA1 | P00915 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imatinib SCHEMBL29377238 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL726190 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1060852 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1673189 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL8217 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL15632914 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1439360 | 0.99 | ABL1 (0.99) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1440465 | 0.99 | ABL1 (0.99) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL5004429 | 0.99 | ABL1 (0.97) | ABL1BCRKITPDGFRARAD52 | |
| SCHEMBL3859559 | 0.97 | ABL1 (0.94) | ABL1BCRKITPDGFRARAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711364-A1 | FUSED PYRROLE RING OR FUSED PYRIDINE RING COMPOUND | Pharmaengine, Inc. (TW) | 2026-03-18 | — | — | EP | claimed |
| WO-2025077721-A1 | MYT1 INHIBITOR BASED ON FUSED THIAZOLE OR PYRIDINE RING | PHARMAENGINE, INC. (CN) | 2025-04-17 | — | — | WO | claimed |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | PEPKON SAS (FR) | 2023-12-28 | — | — | US | claimed |
| EP-4196133-A2 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | University of Central Florida Research Foundation, Inc. (US) | 2023-06-21 | — | — | EP | claimed |
| EP-3544685-B1 | HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF | DEV CT BIOTECHNOLOGY (TW) | 2023-01-04 | — | — | EP | claimed |
| WO-2022036024-A2 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-02-17 | — | — | WO | claimed |
| US-20260132164-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12605397-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | TETRAGON BIOSCIENCE LTD. (IL) | 2026-04-21 | — | — | US | disclosed |
| US-12595517-B2 | Method to treat and stratify a patient suffering from a cancer | INSERM (INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-04-07 | — | — | US | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12595262-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| EP-3901151-B1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2026-04-01 | — | — | EP | disclosed |
| US-20220081412-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-03-17 | — | — | US | disclosed |
| US-20220071975-A1 | DOSAGE REGIMEN OF MDM2 INHIBITOR FOR TREATING CANCERS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-10 | — | — | US | disclosed |
| US-20220062278-A1 | SMALL MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR ACTIVITY AND/OR EXPRESSION AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| EP-3355923-B1 | HISTONE DEACETYLASE INHIBITORS FOR USE IN THE TREATMENT OF DRUG RESISTANT MELANOMA | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2022-02-23 | — | — | EP | disclosed |
| US-20220048973-A1 | B1SP Fusion Protein Therapeutics, Methods, and Uses | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-02-17 | — | — | US | disclosed |
| WO-2022031749-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA | GENENTECH, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-11239066-B2 | Cell population analysis | MICROMASS UK LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595517-B2 | Method to treat and stratify a patient suffering from a cancer | PDCD1, CD274, PDCD4 | ABL1 2383/4885BCR 409/4885KIT 1085/4885 |
| US-12595248-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | ABL1 651/4885BCR 203/4885KIT 2234/4885 |
| US-20220081412-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | HMGB3, HCCS, ACACA | ABL1 3619/4885BCR 413/4885KIT 2088/4885 |
| US-20220062278-A1 | SMALL MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR ACTIVITY AND/OR EXPRESSION AND USES THEREOF | AR, KLK3, FSHR | ABL1 1857/4885BCR 386/4885KIT 2869/4885 |
| US-12595262-B2 | PRMT5 inhibitors | PRMT1, PRMT5, CARM1 | ABL1 326/4885BCR 144/4885KIT 1178/4885 |
| US-12605397-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | CDA, DCTD, RNMT | ABL1 3125/4885BCR 4267/4885KIT 3154/4885 |
| US-20220048973-A1 | B1SP Fusion Protein Therapeutics, Methods, and Uses | PSAP, HSP90B1, PAIP1 | ABL1 4712/4885BCR 474/4885KIT 3330/4885 |
| US-20220071975-A1 | DOSAGE REGIMEN OF MDM2 INHIBITOR FOR TREATING CANCERS | MDM2, TP53, MDM4 | ABL1 588/4885BCR 675/4885KIT 1216/4885 |
| US-20260132164-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | TOP1, NCL, NOLC1 | ABL1 146/4885BCR 23/4885KIT 1896/4885 |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | VIP, RNASE1, ABCB11 | ABL1 958/4885BCR 986/4885KIT 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.